ZLAB - Zai Lab Ltd

ZLAB - Zai Lab Ltd

https://www.zailaboratory.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Zai Lab's Double Whammy: Earnings Miss, Phase 3 Setback - Zai Lab ( NASDAQ:ZLAB )

Benzinga • 4 days, 3 hours ago • score: 0.09

Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products The survival benefits for a new gastric cancer drug, bemarituzumab, were weaker than expected in the final analysis of a Phase Three trial

Zai Lab Limited ( ZLAB ) Stock Jumps 6.8%: Will It Continue to Soar?

Zacks Commentary • 1 month, 3 weeks ago • score: 0.20

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session - BlackSky Technology ( NYSE:BKSY ) , Greenlane Hldgs ( NASDAQ:GNLN )

Benzinga • 1 month, 4 weeks ago • score: -0.47

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Friday. Shares of Netflix, Inc. NFLX fell in pre-market trading following second-quarter results. Netflix reported second-quarter revenue of $11.08 billion, up 16% year-over-year.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-08-29 (Snapshot)

Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.

52W High

$44.34

52W Low

$19.41

MA Status:

50D: Below 200D: Above

Beta (~1 neutral, <0.9 lower risk)

1.04

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.35

EV/Revenue (<3 favorable)

6.80

P/S (TTM) (<3 favorable)

8.06

P/B (<3 favorable)

4.32

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.74%

Institutions (25–75% balanced)

42.65%

Shares Outstanding

111,271,000

Float

1,080,898,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

427,799,000

Gross Profit (TTM)

37,347,000

EPS (TTM)

-2.00

Profit Margin (>10% good)

-0.50%

Operating Margin (TTM) (higher better)

-0.50%

ROE (TTM) (>15% strong)

-0.28%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.09

Momentum

Bearish momentum

Value

-1.0734

Previous

-1.0571

Trend

Falling

Signal Cross

No cross

As of

Aug. 29, 2025